This site displays a prototype of a “Web 2.0” version of the daily Federal Register. It is not an official legal edition of the Federal Register, and does not replace the official print version or the official electronic version on GPO’s govinfo.gov.
The documents posted on this site are XML renditions of published Federal Register documents. Each document posted on the site includes a link to the corresponding official PDF file on govinfo.gov. This prototype edition of the daily Federal Register on FederalRegister.gov will remain an unofficial informational resource until the Administrative Committee of the Federal Register (ACFR) issues a regulation granting it official legal status. For complete information about, and access to, our official publications and services, go to About the Federal Register on NARA's archives.gov.
The OFR/GPO partnership is committed to presenting accurate and reliable regulatory information on FederalRegister.gov with the objective of establishing the XML-based Federal Register as an ACFR-sanctioned publication in the future. While every effort has been made to ensure that the material on FederalRegister.gov is accurately displayed, consistent with the official SGML-based PDF version on govinfo.gov, those relying on it for legal research should verify their results against an official edition of the Federal Register. Until the ACFR grants it official status, the XML rendition of the daily Federal Register on FederalRegister.gov does not provide legal notice to the public or judicial notice to the courts.
National Institutes of Health, HHS.
Notice.
The National Heart, Lung, and Blood Institute, an institute of the National Institutes of Health, Department of Health and Human Services, is contemplating the grant of an exclusive patent license to Phyxius Therapeutics, Inc., a start-up company incorporated as a C corporation under the laws of the state of Delaware, to practice the inventions covered by the patent estate listed in the Supplementary Information section of this notice. This is a first notice intended to apprise the public of a change in prospective licensee of the subject intellectual property rights in the stated field of use.
Only written comments and/or applications for a license which are received by the National Heart, Lung, and Blood Institute on or before August 25, 2021 will be considered.
Requests for copies of the patent application, inquiries, and comments relating to the contemplated an exclusive patent license should be directed to: Michael Davis, J.D., Ph.D., Senior Technology Transfer Manager, 31 Center Drive Room 4A29, MSC2479, Bethesda, MD 20892-2479, phone number 301-451-9032, or michael.davis4@nih.gov.
Intellectual Property
| NIH REF No. | Title | Patent Application No. | Filing Date | Issued Patent No. | Issue Date |
|---|---|---|---|---|---|
| E-114-2004-0-US-01 | Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use | 60/619,392 | 10/15/04 | ||
| E-114-2004-0-PCT-02 | Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use | PCT/US2005/ | 10/14/05 | ||
| E-114-2004-0-AU-03 | Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use | 2005295640 | 10/14/05 | 2005295640 | 11/10/11 |
| E-114-2004-0-CA-04 | Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use | 2584048 | 10/14/05 | 2584048 | 08/09/16 |
| E-114-2004-0-EP-05 | Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use | 05815961.7 | 10/14/05 | 1812474 | 05/26/10 |
| E-114-2004-0-JP-06 | Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use | 2007-536912 | 10/14/05 | 5,091,679 | 09/21/12 |
| E-114-2004-0-US-07 | Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use | 11/577,259 | 04/13/07 | 7,572,771 | 08/11/09 |
| E-114-2004-0-US-08 | Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use | 12/497,443 | 07/02/09 | 8,071,746 | 12/06/11 |
| E-114-2004-0-US-09 | Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use | 12/766,761 | 04/23/10 | 8,148,323 | 04/03/12 |
| E-114-2004-0-CH-11 | Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use | 05815961.7 | 10/14/05 | 1812474 | 05/26/10 |
| E-114-2004-0-DE-12 | Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use | 05815961.7 | 10/14/05 | 1812474 | 05/26/10 |
| E-114-2004-0-ES-13 | Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use | 05815961.7 | 10/14/05 | 1812474 | 05/26/10 |
| E-114-2004-0-FR-14 | Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use | 05815961.7 | 10/14/05 | 1812474 | 05/26/10 |
| E-114-2004-0-GB-15 | Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use | 05815961.7 | 10/14/05 | 1812474 | 05/26/10 |
| E-114-2004-0-IT-16 | Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use | 05815961.7 | 10/14/05 | 1812474 | 05/26/10 |
| E-114-2004-0-US-17 | Multi-Domain Amphipathic Helical Peptides And Methods Of Their Use | 13/407,132 | 02/28/12 | 8,835,378 | 09/16/14 |
All U.S. and foreign patents and applications claiming priority to any member of the above.
The patent rights in these inventions have been assigned or exclusively licensed to the Government of the United States of America.
The prospective exclusive license territory may be worldwide and in fields of use that may be limited to use as a human therapeutic in patients with atherosclerotic cardiovascular disease (ASCVD), including patients undergoing cardiovascular surgery who are at risk of acute kidney injury.
The patents listed above cover an invention directed to peptides or ( printed page 43671) peptide analogs with multiple amphipathic alpha helical domains that promote lipid efflux from cells via an ABCA1-dependent pathway. This invention is also directed to methods of identifying non-cytotoxic peptides that promote ABCA1-dependent lipid efflux from cells, and to methods of using multi-domain amphipathic alpha helical peptides or peptide analogs to treat or inhibit dyslipidemic disorders.
This notice is made in accordance with 35 U.S.C. 209 and 37 CFR part 404. The prospective exclusive license will be royalty bearing. The prospective exclusive license may be granted unless within fifteen (15) days from the date of this published notice, the National Heart, Lung, and Blood Institute receives written evidence and argument that establishes that the grant of the license would not be consistent with the requirements of 35 U.S.C. 209 and 37 CFR part 404.
In response to this Notice, the public may file comments or objections. Comments and objections, other than those in the form of a license application, will not be treated confidentially, and may be made publicly available.
License applications submitted in response to this notice will be presumed to contain business confidential information and any release of information in these license applications will be made only as required and upon a request under the Freedom of Information Act, 5 U.S.C. 552.
Bruce D. Goldstein,
Director, Office of Technology Transfer and Development, National Heart, Lung, and Blood Institute.
[FR Doc. 2021-17011 Filed 8-9-21; 8:45 am]
BILLING CODE 4140-01-P